Research programme: CNS therapeutics - Amorsa Therapeutics

Drug Profile

Research programme: CNS therapeutics - Amorsa Therapeutics

Alternative Names: Amorsa K-ER; K-ER12; KA-ER12; KA-FA

Latest Information Update: 09 Jan 2017

Price : $50

At a glance

  • Originator Amorsa
  • Class Analgesics; Antidepressants
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Depressive disorders; Pain

Most Recent Events

  • 05 Jan 2017 Janssen Pharmaceuticals enters into a worldwide licensing option agreement with Amorsa Therapeutics for development and commercialisation of a small molecule drug candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top